Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Facility noncompliance in US drops to 2009 levels

This article was originally published in Clinica

Executive Summary

Medical device Form 483s – documents that US FDA inspectors issue to companies to indicate areas of noncompliance at facilities – dropped in fiscal 2014 for the first time in six years. The number issued for medical devices in FY2014 (year to 30 September 2014) was 972, a drop of 11.6% on the FY2013 total of 1,099. The last time that medical device 483s were at a similar level was in FY2010.

You may also be interested in...



The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024

Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.

An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel